glp 1 agonists on the market GLP-1 Weight Loss Drugs Report, 2025-2030 GLP-1 Receptor Agonist Market Growth

Although rare, associations with nonarteritic anterior ischemic optic neuropathy, pancreatitis, medullary thyroid carcinoma, and acute kidney injury (AKI) have been reported, primarily through pharmacovigilance and case-based evidence

Earlier this year, Blue Cross Blue Shield said five GLP-1 drugs now account for nearly 20% of its pharmacy spend.

Discover the pros and cons of GLP medications for weight loss and long-term health results.

A new FDA-approved obesity pill could offer a lower-cost alternative to injectable GLP-1 drugs like Ozempic and Mounjaro

Well, thats exactly what happened with the GLP-1 receptor agonists

CivicScience offers insights into the impact of cost, side effects & trends in GLP-1 usage.